在复发的IDH1/NPM1共变型AML中,用单一药物olutasidenib进行功能治疗
Justin Watts1, Tiffany Nong2, Katarina Micin2
1University of Miami Sylvester Comprehensive Cancer Center, Division of Hematology, Miami, FL, USA. jxw401@miami.edu.
NPJ precision oncology
|July 2, 2025
概括
奥卢塔西迪尼布为患有特定突变的急性髓性白血病 (AML) 患者提供长期缓解. 这项案例研究显示,一个患者在7年内获得了用olutasidenib单一治疗的完全反应,这表明了潜在的功能治愈.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性髓性白血病 (AML) 是一种异质的血液性恶性瘤.
- 复发性或耐火性AML与异酸脱酶1 (IDH1) 突变具有治疗挑战.
- 奥卢塔西迪尼布是一种FDA批准的口服小分子抑制剂,向突变IDH1.1.
研究的目的:
- 报告第一个用olutasidenib治疗的患者的长期结果.
- 为了研究患有复发性NPM1和IDH1共变异AML的患者的临床,病理和基因组进化,用olutasidenib单独治疗.
- 评估一个患者的最小残留疾病 (MRD) 达到持久的完整反应.
主要方法:
- 一个患有复发性/耐药性AML的患者接受olutasidenib单一治疗的病例报告.
- 长线临床过程监测.
- 病理学和基因组分析.
- 使用单细胞MRD测定,数字PCR和qPCR进行突变检测 (IDH1,NPM1).
主要成果:
- 患者在使用olutasidenib单独治疗的7年时间内实现并保持了持续的完全响应 (CR).
- 没有发现残留可检测白血病的证据,使用敏感的分子测定.
- 详细的临床过程和疾病演变被记录下来.
结论:
- 在选择的AML患者中,单独使用olutasidenib可以诱导持久的长期缓解.
- 这一案例是第一个使用IDH1抑制剂治疗AML的潜在功能治疗案例.
- 长期监测和敏感的MRD测定对于评估治疗疗效至关重要.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Tumor Immunotherapy
667
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
667


